| Dr David James Gazeley, MD | |
|
9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 | |
| (414) 955-7012 | |
| Not Available |
| Full Name | Dr David James Gazeley |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 18 Years |
| Location | 9200 W Wisconsin Ave, Milwaukee, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932228723 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 52910 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Froedtert Memorial Lutheran Hospital | Milwaukee, WI | Hospital |
| United Hospital System | Kenosha, WI | Hospital |
| Community Memorial Hospital | Menomonee falls, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Medical College Of Wisconsin Inc | 2668384371 | 1813 |
| Froedtert Andthe Medical College Of Wisconsin Community Physicians Inc | 3678760063 | 1040 |
News Archive
Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].
The journal Andologia has published the first report of abnormal sperm parameters in obese men based on computer aided sperm analysis. The findings suggest that clinicians may need to factor in paternal obesity prior to assisted reproduction.
› Verified 9 days ago
| Entity Name | University Of Wisconsin Medical Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598784555 PECOS PAC ID: 6608785464 Enrollment ID: O20031111000435 |
News Archive
Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].
The journal Andologia has published the first report of abnormal sperm parameters in obese men based on computer aided sperm analysis. The findings suggest that clinicians may need to factor in paternal obesity prior to assisted reproduction.
› Verified 9 days ago
| Entity Name | The Medical College Of Wisconsin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699720086 PECOS PAC ID: 2668384371 Enrollment ID: O20031120000259 |
News Archive
Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].
The journal Andologia has published the first report of abnormal sperm parameters in obese men based on computer aided sperm analysis. The findings suggest that clinicians may need to factor in paternal obesity prior to assisted reproduction.
› Verified 9 days ago
| Entity Name | Froedtert &the Medical College Of Wisconsin Community Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568787448 PECOS PAC ID: 3678760063 Enrollment ID: O20101210000699 |
News Archive
Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].
The journal Andologia has published the first report of abnormal sperm parameters in obese men based on computer aided sperm analysis. The findings suggest that clinicians may need to factor in paternal obesity prior to assisted reproduction.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David James Gazeley, MD 929 Robertson St, Wauwatosa, WI 53213-3025 Ph: (608) 332-6903 | Dr David James Gazeley, MD 9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 Ph: (414) 955-7012 |
News Archive
Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].
The journal Andologia has published the first report of abnormal sperm parameters in obese men based on computer aided sperm analysis. The findings suggest that clinicians may need to factor in paternal obesity prior to assisted reproduction.
› Verified 9 days ago
Julia Bonner, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 3351 North Downer Avenue, Milwaukee, WI 53211 Phone: 414-229-5684 | |
Dr. Zachary Smith, DO Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-955-6830 Fax: 414-955-6214 | |
Dr. Christopher Patrick Boyd, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-805-6000 Fax: 414-805-6280 | |
Umair Bajwa, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-805-0812 Fax: 414-805-0855 | |
Rasika Surajyam Chepuri, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-955-7040 Fax: 414-955-6211 | |
Soryal A Soryal, M.D Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1020 N 12th St, 3rd Floor, Milwaukee, WI 53233 Phone: 414-219-7300 | |
Aboud Affi, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1218 W Kilbourn Ave, Suite 404, Milwaukee, WI 53233 Phone: 414-291-3100 |